AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28152319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidant supplementation (Squalene 100 mg, Vitamin C 30 mg, Coenzyme Q10 10 mg, Zinc 5 mg, Beta Carotene 3.6 mg, Bioflavonoids 30 mg, Selenium 55 mcg) administered daily for 2 weeks
Number of subjects: 20
Study 28152319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidant supplementation)
Number of subjects: 20
Study 25749317 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A intake in hypertensive subpopulation (1732.77±962.27 µg)
Number of subjects: 1514
Study 25749317 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake in hypertensive subpopulation (8.13±9.71 µg)
Number of subjects: 1514
Study 25749317 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E intake in hypertensive subpopulation (18.79±7.84 mg)
Number of subjects: 1514
Study 24229754 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 434
Study 24229754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 21557117 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer course
Number of subjects: 259
Study 21557117 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 259
Study 21557117 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 259
Study 19407333 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week community-based, peer-led diabetes self-management program (DSMP)
Number of subjects: 345
Study 19407333 — intervention group
Group type: COMPARATOR
Intervention: usual-care control group
Number of subjects: 345
Study 17803388 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 10 J/cm(2) or 15 J/cm(2)
Number of subjects: 80
Study 17803388 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment at 0.1 J/cm(2)
Number of subjects: 80
Study 14748768 — intervention group
Group type: EXPERIMENTAL
Intervention: OCSP classification (LACS, PACS, TACS, POCS)
Number of subjects: 759
Study 14748768 — intervention group
Group type: EXPERIMENTAL
Intervention: TACS
Number of subjects: 759
Study 14748768 — intervention group
Group type: EXPERIMENTAL
Intervention: PACS
Number of subjects: 759
Study 14748768 — intervention group
Group type: EXPERIMENTAL
Intervention: LACS
Number of subjects: 759
Study 14748768 — intervention group
Group type: EXPERIMENTAL
Intervention: POCS
Number of subjects: 759
Study 11515850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release granules (2 packets twice daily)
Number of subjects: 227
Study 11515850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release granules (1 packet four times daily)
Number of subjects: 227
Study 11515850 — intervention group
Group type: COMPARATOR
Intervention: Prolonged-release tablets (2 tablets four times daily)
Number of subjects: 227
Study 9935253 — intervention group
Group type: COMPARATOR
Intervention: Treatment A: two 100-mg trovafloxacin tablets given orally with 240 mL water
Number of subjects: 24
Study 9935253 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B: two crushed 100-mg trovafloxacin tablets suspended in water and administered through a nasogastric tube into the stomach
Number of subjects: 24
Study 9935253 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C: two crushed 100-mg trovafloxacin tablets suspended in water and administered through a nasogastric tube into the duodenum
Number of subjects: 24
Study 9935253 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment D: two crushed 100-mg trovafloxacin tablets suspended in water and given through a nasogastric tube into the stomach with enteral feeding solution
Number of subjects: 24
Study 8118758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release monofluorophosphate (MFP-SR) 76 mg
Number of subjects: 6
Study 8118758 — intervention group
Group type: COMPARATOR
Intervention: Plain monofluorophosphate (MFP) 76 mg
Number of subjects: 6
Study 2865889 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 2865889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31415193 — intervention group
Group type: EXPERIMENTAL
Intervention: Linking Information and Families Together intervention (weekly text messages, telephone calls, or e‐mails about missed assignments, grades, and behavior)
Number of subjects: 318
Study 31415193 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 318
Study 29198854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane (TAP) blocks
Number of subjects: 67
Study 29198854 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural anesthesia (TEA)
Number of subjects: 67
Study 27634828 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 304
Study 27634828 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 304
Study 25299792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile feedback through electrical stimulation triggered by body sway
Number of subjects: 22
Study 23149426 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 201
Study 20549830 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-Cw 06 positive cohort
Number of subjects: 284
Study 20549830 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-Cw 06 negative cohort
Number of subjects: 284
Study 20549830 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoimmunity group
Number of subjects: 284
Study 20549830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonautoimmunity group
Number of subjects: 284
Study 17650736 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy management with integrated components of cognitive‐behavioural origin
Number of subjects: 33
Study 17650736 — intervention group
Group type: COMPARATOR
Intervention: Regular primary care physiotherapy
Number of subjects: 33
Study 17650736 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high self‐efficacy
Number of subjects: 33
Study 17237315 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated isoflavone supplementation (84 mg/d)
Number of subjects: 37
Study 15492576 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine/fentanyl
Number of subjects: 20
Study 15492576 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (patient-controlled analgesia)
Number of subjects: 20
Study 10928578 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1800 mg per day
Number of subjects: 25
Study 10928578 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 3600 mg per day
Number of subjects: 25
Study 10928578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8756922 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound measurement of hepatic artery resistive index
Number of subjects: 5
Study 8756922 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound measurement of systolic acceleration time
Number of subjects: 5
Study 1569453 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous methotrexate (HD; 4 g/m2)
Number of subjects: 51
Study 1569453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose intravenous methotrexate (LD; 40 mg/m2)
Number of subjects: 51
Study 1569453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation (CRT) 1,800 cGy or 2,800 cGy
Number of subjects: 51
Study 1569453 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex (female)
Number of subjects: 51
Study 3839174 — intervention group
Group type: EXPERIMENTAL
Intervention: dezocine (0.125 mg/kg)
Number of subjects: 30
Study 3839174 — intervention group
Group type: EXPERIMENTAL
Intervention: ciramadol (0.6 mg/kg)
Number of subjects: 30
Study 3839174 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine (0.125 mg/kg)
Number of subjects: 30
Study 31997237 — intervention group
Group type: EXPERIMENTAL
Intervention: Qixiong Zhongzi Decoction (QZD) 150 mL twice a day for 12 weeks
Number of subjects: 66
Study 31997237 — intervention group
Group type: COMPARATOR
Intervention: Levocarnitine oral liquid 1 g twice a day for 12 weeks
Number of subjects: 66
Study 31997237 — intervention group
Group type: EXPERIMENTAL
Intervention: Qixiong Zhongzi Decoction (QZD)
Number of subjects: 66
Study 31997237 — intervention group
Group type: COMPARATOR
Intervention: Levocarnitine oral liquid
Number of subjects: 66
Study 31997237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 30898578 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state EEG
Number of subjects: 145
Study 30898578 — intervention group
Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery (MCCB)
Number of subjects: 145
Study 30898578 — intervention group
Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 145
Study 28754306 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) of the ventral anterior limb of the internal capsule (vALIC)
Number of subjects: 61
Study 28754306 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 61
Study 28754306 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 61
Study 26138125 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 434
Study 26138125 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically indicated GA
Number of subjects: 434
Study 26138125 — intervention group
Group type: COMPARATOR
Intervention: Local Anesthesia
Number of subjects: 434
Study 24712573 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU weekly for 8 weeks)
Number of subjects: 150
Study 24712573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 22052304 — intervention group
Group type: COMPARATOR
Intervention: Alexandrite laser alone (four sessions, two months apart)
Number of subjects: 111
Study 22052304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with diode laser for the first two sessions and alexandrite laser for the next two sessions
Number of subjects: 111
Study 22052304 — intervention group
Group type: COMPARATOR
Intervention: Alexandrite laser alone
Number of subjects: 111
Study 22052304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with diode and alexandrite lasers
Number of subjects: 111
Study 22052304 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 111
Study 19380259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping therapy (wet cupping), single application
Number of subjects: 52
Study 19380259 — intervention group
Group type: COMPARATOR
Intervention: Control (local application of heat over trapezius muscle), single application
Number of subjects: 52
Study 19380259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping therapy
Number of subjects: 52
Study 17374834 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 579
Study 17374834 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 579
Study 15080781 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass reduction alone
Number of subjects: 20
Study 15080781 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass reduction plus rGH
Number of subjects: 20
Study 15080781 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass reduction plus nandrolone undecanoate
Number of subjects: 20
Study 11281433 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide/1% clindamycin
Number of subjects: 492
Study 11281433 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide
Number of subjects: 492
Study 11281433 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide/3% erythromycin
Number of subjects: 492
Study 9277426 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid distension (100 ml)
Number of subjects: 9
Study 9277426 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm stimulation (47 +/- 1 degrees C)
Number of subjects: 9
Study 9277426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold stimulation (18 +/- 2 degrees C)
Number of subjects: 9
Study 7960314 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin (1000mg of ASA)
Number of subjects: 18
Study 7960314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable buffered aspirin (1000mg of ASA and 600 mg of calcium carbonate)
Number of subjects: 18
Study 7960314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2955979 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2 mg)
Number of subjects: 6
Study 2955979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30409107 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa 'on' (n = 14)
Number of subjects: 27
Study 30409107 — intervention group
Group type: COMPARATOR
Intervention: Levodopa 'off' (n = 13)
Number of subjects: 27
Study 26981530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer related fatigue (CRF)
Number of subjects: 148
Study 26981530 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients reporting CRF
Number of subjects: 148
Study 26981530 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative themes from interviews
Number of subjects: 148
Study 24091250 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training based real-world video recording (TRWVR) for 30 min per day, three times per week, for 6 weeks
Number of subjects: 30
Study 24091250 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking training for 30 min per day, three times per week, for 6 weeks
Number of subjects: 30
Study 22418044 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 60
Study 22418044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20869783 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians from the higher ranked institution
Number of subjects: 30000
Study 20869783 — intervention group
Group type: COMPARATOR
Intervention: Physicians from the lower ranked institution
Number of subjects: 30000
Study 18418219 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha + gefitinib (500 mg daily)
Number of subjects: 17
Study 18418219 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha + imatinib (600 mg daily)
Number of subjects: 17
Study 16185205 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐ACASI
Number of subjects: 2287
Study 12230146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential presentation of symbols on video lottery terminals
Number of subjects: 0
Study 12230146 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous presentation of symbols on video lottery terminals
Number of subjects: 0
Study 10220634 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol 10/100 mg
Number of subjects: 397
Study 10220634 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 397
Study 10220634 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg
Number of subjects: 397
Study 7783459 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite acupuncture treatment (acupuncture, auriculo‐acupoint pellet pressure, herbal plasters)
Number of subjects: 128
Study 2225438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hancock bioprosthetic valves (n = 35)
Number of subjects: 75
Study 2225438 — intervention group
Group type: COMPARATOR
Intervention: Carpentier‐Edwards bioprosthetic valves (n = 40)
Number of subjects: 75
Study 353087 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal dressing 1
Number of subjects: 41
Study 353087 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal dressing 2
Number of subjects: 41
Study 353087 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal dressing 3
Number of subjects: 41
Study 31771639 — intervention group
Group type: EXPERIMENTAL
Intervention: New multi‐component service pathway (self‐management kit, customized GP checklist, educational topics)
Number of subjects: 110
Study 31771639 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study 31771639 — intervention group
Group type: EXPERIMENTAL
Intervention: New multi‐component service pathway
Number of subjects: 110
Study 28012773 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 557
Study 28012773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study 25778333 — intervention group
Group type: COMPARATOR
Intervention: Combined general-epidural anesthesia (C)
Number of subjects: 40
Study 25778333 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (G)
Number of subjects: 40
Study 23398140 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 80
Study 23398140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20697791 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal imitation training
Number of subjects: 6
Study 20697791 — intervention group
Group type: EXPERIMENTAL
Intervention: Video modeling
Number of subjects: 6
Study 19244883 — intervention group
Group type: EXPERIMENTAL
Intervention: GTRF treatment (bioabsorbable membrane and demineralized xenograft)
Number of subjects: 16
Study 19244883 — intervention group
Group type: COMPARATOR
Intervention: CAF treatment (control)
Number of subjects: 16
Study 19244883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (CAF and GTRF)
Number of subjects: 16
Study 19244883 — intervention group
Group type: EXPERIMENTAL
Intervention: GTRF treatment
Number of subjects: 16
Study 16906456 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover design
Number of subjects: 200
Study 16906456 — intervention group
Group type: COMPARATOR
Intervention: Parallel group design
Number of subjects: 200
Study 14720302 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler (PD)
Number of subjects: 18
Study 14720302 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging (Duplex and Color Doppler)
Number of subjects: 18
Study 11342889 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstented
Number of subjects: 58
Study 11342889 — intervention group
Group type: COMPARATOR
Intervention: Stented
Number of subjects: 58
Study 11342889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 9331924 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold visual stimuli in the oddball-like paradigm
Number of subjects: 0
Study 9331924 — intervention group
Group type: COMPARATOR
Intervention: Suprathreshold stimuli in the single-stimulus paradigm
Number of subjects: 0
Study 8096228 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (1 to 5 mg/day, n = 11)
Number of subjects: 24
Study 8096228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 24
Study 3959558 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (intoxicated condition)
Number of subjects: 40
Study 3959558 — intervention group
Group type: COMPARATOR
Intervention: Sober condition (control)
Number of subjects: 40
Study 30672976 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator model group
Number of subjects: 2
Study 30672976 — intervention group
Group type: COMPARATOR
Intervention: Animal model group
Number of subjects: 2
Study 28334430 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide margins (≥10 mm, WM)
Number of subjects: 96
Study 28334430 — intervention group
Group type: COMPARATOR
Intervention: Narrow margins (≥5 mm but <10 mm, NM)
Number of subjects: 96
Study 25810449 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record-based tools including reminders to measure height and weight, alerts for adding overweight or obesity to the problem list, tailored management recommendations, and a Weight Management screen
Number of subjects: 23
Study 25810449 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record-based tools
Number of subjects: 23
Study 25810449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electronic health record-based tools)
Number of subjects: 23
Study 23487178 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning by physicians that half of all smokers would be killed by smoking, advice to quit immediately and referral to a cessation clinic.
Number of subjects: 126
Study 23487178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study 21332712 — intervention group
Group type: EXPERIMENTAL
Intervention: GRASPA(®) 50 iu/kg
Number of subjects: 24
Study 21332712 — intervention group
Group type: EXPERIMENTAL
Intervention: GRASPA(®) 100 iu/kg
Number of subjects: 24
Study 21332712 — intervention group
Group type: EXPERIMENTAL
Intervention: GRASPA(®) 150 iu/kg
Number of subjects: 24
Study 21332712 — intervention group
Group type: COMPARATOR
Intervention: E. colil‐ASNase (control)
Number of subjects: 24
Study 19595257 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosteal(TM) plus TP regimen
Number of subjects: 36
Study 19595257 — intervention group
Group type: COMPARATOR
Intervention: TP regimen only
Number of subjects: 36
Study 16652135 — intervention group
Group type: EXPERIMENTAL
Intervention: oral freeze-dried NT 6 gm/day
Number of subjects: 24
Study 16652135 — intervention group
Group type: EXPERIMENTAL
Intervention: bed-dried NT 6 gm/day
Number of subjects: 24
Study 16652135 — intervention group
Group type: EXPERIMENTAL
Intervention: freeze-dried NT 12 gm/day
Number of subjects: 24
Study 16652135 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 15322434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15322434 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid blockade with naloxone
Number of subjects: 28
Study 15322434 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Blockade Effects (ie, absence of endogenous opioid analgesia to acute pain) in the High Disability group
Number of subjects: 28
Study 15322434 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Blockade Effects (ie, effective opioid analgesia to acute pain) in the Low Disability group
Number of subjects: 28
Study 11094665 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine skin infiltration
Number of subjects: 40
Study 11094665 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40